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Abstract 
BACKGROUND: Peripheral resistance to thyroid hormones is a type of unresponsiveness of the peripheral cells 
or tissues to FT3 and/or FT4. Generalised resistance to thyroid hormones affects the pituitary gland and most of 
the peripheral tissues. Selective pituitary resistance or central resistance to thyroid hormones include 
unresponsiveness of the pituitary gland, but the peripheral tissues are responsive. Selective peripheral resistance 
involves peripheral tissue or cellular resistance to thyroid hormones, but the pituitary gland is responsive. 
CASE PRESENTATION: We present a rare case of a female patient with partial peripheral resistance to thyroid 
hormones due to a point mutation coding for the beta subunit of the integrin molecule α(V)β(3) and concomitant 
Hashimoto`s thyroiditis. Clinically, the patient`s symptoms were in favour of hypothyroidism, and the laboratory 
results were in favour of the secondary hyperthyroid state. PCR protein amplification detected a point mutation 
coding for the membrane receptor, which mediates a signal via the MAPK pathway when bonded with thyroid 
hormones. 
CONCLUSION: Peripheral resistance to thyroid hormones is a very rare condition and can often be misdiagnosed 
due to the broad spectrum of clinically similar differential diagnostic entities. Molecular analysis is required to 
confirm the exact underlying cause for the impaired peripheral sensitivity to thyroid hormones syndrome. 
 
 
 
 
 
 
 
 
 
Introduction 
 
 Thyroid hormones, peptide-like in structure 
but both peptide-like and steroid-like in function, are 
indispensable for normal fetal development and 
responsible for the regulation of the tissues basal 
metabolism. The bioactive form at the cellular level is 
T3/FT3 (triiodothyronine/free triiodothyronine), a final 
product of the processes of the outer ring deiodination 
of the prohormone T4/FT4 (tetraiodothyronine/free 
tetraiodothyronine). Selenoenzymes (deiodinases) 
perform this peripheral conversion [1]. Even though 
the structure of the thyroid hormones is peptide in 
nature (two iodotyrosine components are fused into 
one thyronine molecule), the peripheral effects are 
expressed or mimic the activity of both peptide-like 
hormones (via the membrane receptors or membrane 
transporter proteins and consecutive second 
messenger cascade activation) and steroid-like 
hormones (via the nuclear receptors and binding to 
hormone response elements (HREs) with consecutive 
induction of transcription and gene expression 
modulation) [2]. 
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 The nuclear receptors or thyroid hormones 
(THR) are presented in two different protein forms α 
and β, encoded by the THRA and THRB genes 
located at chromosomes 3 and 17, respectively. Their 
tissue distribution is not equal, as they undergo 
splicing at several points and are positioned at 
different locations in the body. The main isoforms of 
the THR responsible for mediating cell response when 
bound to thyroid hormones are THRα1 – widely 
expressed in the bones, skeletal and cardiac muscles, 
THRβ1 – expressed in the kidneys, brain, liver, and 
THRβ2 – expressed in the anterior pituitary, 
hypothalamus, and retina [3]. 
 Thyroid hormone deficit (hypothyroidism) is 
not clinically manifested for a few months, even after 
total thyroidectomy being performed, mostly due to 
their steroid-like actions (induction of transcription and 
gene expression modulation) and also due to the 
release of free hormones fractions from the total 
hormones fractions bound to the specific hormone 
carriers: prealbumin, albumin or thyroxine-binding 
globulin (TBG). The fractions of thyroid hormones 
bound to their carriers are termed as circulating 
``thyroid hormone reserve`` or total hormone fractions 
(TT4 and TT3), and those that circulate unbound in 
the bloodstream are referred to as free hormone 
fractions (FT4 and FT3). The peripheral cellular and 
tissue effects of thyroid hormones are mostly due to 
the levels and actions of the free hormone fractions 
[4]. 
 Peripheral resistance to thyroid hormones is a 
type of unresponsiveness of the peripheral cells or 
tissues to FT3 and/or FT4. Thyroid hormone 
resistance (RTH) in general, or sometimes called as 
Refetoff syndrome, is a condition where thyroid 
hormone levels are elevated and fail to suppress the 
production of TSH (fully or partially) at the level of the 
pituitary gland. Refetoff et al. suggested using a new 
nomenclature referring to the condition as "impaired 
sensitivity to thyroid hormones" [5]. It can occur in 
several forms. Generalised resistance to thyroid 
hormones (GRTH), which is affecting the pituitary 
gland and most of the peripheral tissues, is usually 
consistent with a clinically euthyroid state but with 
elevated T3 and T4 levels in the blood, as well as high 
or normal TSH. Selective pituitary resistance or 
usually termed as central resistance to thyroid 
hormone (CRTH or PRTH), includes 
unresponsiveness of the pituitary gland to thyroid 
hormones, but the peripheral tissues are responsive. 
It is manifested with elevated serum thyroid hormone 
levels, and normal or elevated TSH levels, but the 
peripheral tissues experience an abnormal influx of 
thyroid hormones and is clinically associated with 
symptoms of hyperthyroidism. Selective peripheral 
resistance to thyroid hormone (PerRTH) involves 
peripheral tissue or cellular resistance to thyroid 
hormones, but the pituitary gland is responsive. 
Clinically the patients present symptoms typical for 
hypothyroidism, which usually does not correlate with 
the circulating hormone levels – elevated TSH, FT3, 
and FT4 [5]. 
 Integrins are part of the transmembrane 
proteins family that are involved in the processes of 
adhesion between the cells and the extracellular 
matrix termed intercellular adhesion molecules 
(ICAMs). Generally, they recognise a tripeptide Arg – 
Gly – Asp (RGD) binding site when connected to their 
ligands. A typical integrin molecule is built by two non 
covalently connected glycoprotein subunits α and β, 
respectively [6]. The structure of the integrins 
encompasses unique heterodimers with an immense 
variety of ligand recognition, bondage, and response. 
Overall, they are built by at least eighteen α and eight 
β subunits, which are afterwards subgrouped 
depending on their specific role and tissue distribution. 
The most typical forms of integrin association include 
the β1 integrins, β2 integrins, and αv-containing 
integrins [7]. 
 The integrin, α(V)β(3), is a heterodimer made 
up by an α(V) (also called CD51, MSK8, vitronectin 
receptor α (VNRα)) 1048 long amino acid sequence 
located on chromosome 2q31.32, and β(3) (also 
called CD61, GP3A, GPIIIa, platelet glycoprotein IIIa) 
with 788 long amino acid sequence, located on 
chromosome 17q21.32 [7]. Furthermore, the 
extracellular portion of the integrin consists of multiple 
domains, including RGD-recognizing site. It is widely 
distributed in the body, and upon binding to a specific 
ligand, it mediates a secondary intracellular response 
that modulates the cellular activity. Ligands for this 
specific integrin encompass: fibrinogen, vitronectin, 
vWF, thrombospondin, fibrillin, tenascin, PECAM-1, 
fibronectin, osteopontin, BSP, MFG-E8, ADAM-15, 
COMP, Cyr61, ICAM-4, MMP, FGF-2, uPA, uPAR, L1, 
angiostatin, plasmin, cardiotoxin, LAP-TGF-β, Del-1, 
including thyroid hormone peripheral recognition and 
bondage as well [8].  
 
 
Case Presentation 
 
 A 36 years old female patient, I.I. was referred 
for evaluation of the function of the thyroid gland. The 
anamnesis gave information about a high degree of 
education, no children and a positive family history of 
hypothyroidism due to Hashimoto`s thyroiditis in 
mother and sister. She presented symptoms and 
clinical signs that pointed towards a hypothyroid state 
such as recent weight gain, constipation, dryness of 
hair and fickle nails, but mostly, inability to do her daily 
routine due to feeling tired and sleepy all the time. A 
recent progressive swelling in the neck that resulted in 
having swallowing difficulties was also highlighted. 
There were no previous records of her having any 
thyroid hormone dysregulation, so a thyroid function 
laboratory panel was ordered in June 2015. The 
results presented extremely high levels of TSH, along 
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with elevated FT3, FT4, TT3, and TT4. A biochemical 
laboratory panel that was typical for a severe possible 
secondary hyperthyroid state (Table 1). 
Table 1: Biochemical laboratory results 
 Reference value Patients results 
TSH 0.4 - 4.0 mIU/L >75 mIU/L 
FT3 3.5 - 7.8 pmol/L 30.7  pmol/L 
FT4 11 - 25 pmol/L > 60 pmol/L 
TT3 0.9-1.9 nmol/L 2.34 nmol/L 
TT4 71-141 nmol/L 203 nmol/L 
TGL <1.7 mmol/L 3.65 mmol/L 
Cholesterol <5.5 mmol/L 6.6 mmol/L 
Fe 17-30 micromol/L 2.9 micromol/L 
Hgb 13.5 - 17.5 g/dL (m) 12 - 15.5 
g/dL (f) 
8.6 g/dL 
Prealbumin 150 - 360  mg/L 213 mg/L 
Albumin 3.3-5.7 g/dL 4.1 g/dL 
TBG  150-360 nmol/ml 256 nmol/ml 
aTPO >35 IU/mL >1000 IU/mL 
aTg >20 IU/mL >3000 IU/mL 
Prolactin  1.9-25 ng/ml 14.3 ng/ml 
Progesterone Follicular phase: 0,10-1,13; 
Ovulation: 0.48 – 1,72; Post 
menopause: 0.36 -1.0; On oral 
contraceptives: 0.34-0.90 ng/ml 
> 0.2 ng/ml 
SHBG 15 - 100 nmol/L 19,57 nmol/L 
Estrogen Follicular phase: 26.5-160; 
Ovulation: 186 – 400; Post 
menopause: >30; On oral 
contraceptives: >102 pg/ml 
55.0  pg/ml 
FSH Follicular phase: 1.98-11.3; 
Ovulation: 7.5 – 21; Post 
menopause: 9.7 - 111; On oral 
contraceptives: 1.7- 4.9 mIU/L 
3.88 mIU/L 
LH Follicular phase: 1,1-11.6; 
Ovulation: 17-77; Post 
menopause: 11.3-39.8; On oral 
contraceptives: 0.5-8.0 mIU/L 
5.57 mIU/L 
Estradiol 26.5-160 pg/mL 55 pg/mL 
CK 24-173  U/L 178   U/L 
 
 Clinically, the patient`s symptoms were in 
favour of hypothyroidism, which did not correlate with 
the laboratory results in favour of possible secondary 
hyperthyroid state or maybe hashitoxicosis. 
 The ultrasonography of the thyroid gland 
(performed on Phillips H.D. 6, Version 1.1, probe 7,5 
Hz) gave information about an enlarged, 
nonhomogeneous thyroid gland with hypoechoic 
structure, initial fibrosis and visible pseudonodules 
(Fig. 1). 
a)
 
b) 
 
Figure 1: An ultrasonographic cross-sectional and longitudinal 
image of the thyroid gland presenting a nonhomogeneous thyroid 
gland with hypoechoic structure and pseudonodules 
 
 Fine needle aspiration biopsy (FNAB) was 
conducted for a cytopathological examination (H&E 
staining) due to the presence of pseudonodules on 
ultrasonography. The results pointed towards the 
presence of prominent germinal follicles with active 
germinal centres, lymphocytic infiltration, oncocytic 
cells with Hurthle cell metaplasia, and initial fibrosis. 
These findings in correlation with the high aTPO and 
aTg laboratory values revealed underlying (previously 
unsuspected) Hashimoto’s thyroiditis – interpreted by 
the pathologist as group III by the BETHESDA system 
of classification (Fig. 2). 
  
Figure 2: Microscopic features of the FNAB presenting germinal 
centres and lymphocytic infiltration - Hashimoto’s thyroiditis 
 
 Thyroid scintigraphy performed with 
99m
Tc-
pertechnetate (185 MBq/5 mCi tracer activity, images 
obtained 30 min post-injection on dual-headed 
gamma camera MEDISO DHV Nucline Spirit, with 140 
keV photopeak and low-energy, high resolution 
(LEHR) parallel collimator) was the following step. The 
patient’s thyroid gland was enlarged with increased 
tracer accumulation intensity in favour of 
hyperthyroidism caused by the elevated TSH levels 
(Fig. 3). 
 
Figure 3: Thyroid scintigraphy with 
99m
Tc-pertechnetate presenting 
diffusely increased tracer accumulation 
 
 An MRI study followed, and the pituitary gland 
was visualised as normal, in a standard and additional 
sequences, in a native and post contrast study series 
and the suspicion for possible adenoma (TSH-oma) of 
the pituitary gland was ruled out (Fig. 4). 
 To combine the anatomical examinations with 
functional ones, to exclude or to confirm the possible 
differential diagnosis, a TRH test and T3 suppression 
test were also conducted. 
 The TRH stimulation test included 
administration of small amounts of TRH intravenously, 
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following which levels of TSH were measured at 
several subsequent points (15-30 minutes post-
injection) using samples of blood taken from a 
peripheral vein. Before the test, TRH levels were 
measured and were slightly suppressed. The test was 
performed to differentiate the possible abnormality in 
the hypothalamus-pituitary axis. The results presented 
an increase in TSH levels.  
 
Figure 4: Normal MRI study of the pituitary gland 
 
  Considering the T3 suppression test, T3 was 
given to the patient during whom TSH levels were 
measured. In our case, the levels of TSH remained 
high. 
 With rT3 levels within the normal range and a 
normal FT4 to FT3 conversion, deiodinase enzyme 
abnormality and selenium deficiency were excluded.      
 PCR protein amplification was afterwards 
ordered for the class of integrins α(V)β(3), involved in 
T3 bondage and signal transduction. It presented a 
point mutation coding for the beta subunit of the 
membrane receptor molecule, which was later 
confirmed to be the exact reason for the impaired 
sensitivity to thyroid hormones syndrome (ISTHS) in 
the patient (Fig. 5). 
 
 
Figure 5: PCR presenting point mutation 
 
 The patient was prescribed substitution 
therapy of 50 μg/day of levothyroxine sodium and is 
regularly followed on check-ups up to date, adjusting 
the dosage of the therapy depending on the clinical 
signs and symptomatology of the patient. 
 
 
Discussion 
 
 The presented case is part of the broad 
spectrum of impaired sensitivity to thyroid hormones 
syndrome - ISTHS or to be more precise a rare partial 
peripheral resistance to thyroid hormones due to a 
point mutation coding for the beta subunit of the 
integrin molecule α(V)β(3). The ISTHS has an 
incidence of 1:40000 and usually the underlying cause 
is due to different thyroid hormone receptors 
mutations. Several case reports have been previously 
published in the literature with various types of 
mutations in question featuring a broad spectrum of 
unusual and misleading clinical and biochemical 
manifestations [9], [10], [11], [12]. 
 Our patient was admitted with a recently 
formed goitre which in correlation with her 
ultrasonography findings (enlarged thyroid gland with 
hypoechoic structure and fibrosis - most likely due to 
Hashimoto thyroiditis) and the clinical symptoms of 
hypothyroidism, pointed towards the decreased 
activity of the thyroid gland as the probable initial 
diagnosis. A hormone panel typical for secondary 
hyperthyroidism, with extremely high TSH, FT4, and 
FT3, also with the accented presence of aTPO and 
aTg (indicating an autoimmune component to the 
condition – in favour of Hashimoto thyroiditis) was 
obtained. Also, the patient had elevated creatine 
kinase (CK) levels, high cholesterol, and triglyceride 
levels (pointing towards dyslipidemia), which along 
with the iron deficiency anaemia (very low iron and 
haemoglobin levels) indicated a hypothyroid metabolic 
state. The symptoms presented by the patient, 
together with the detected dyslipidemia, anaemia and 
elevated CK levels were in favour of hypothyroidism, 
which did not correlate with the thyroid biochemical 
panel which was in favor of the secondary 
hyperthyroid laboratory state [13], [14], [15]. 
 The cellular architectonic of the tissue 
provided via the FNAB (due to the pseudonodules 
detected on the US) correlated with the elevated 
antibody levels. Adding the information of the positive 
family history of hypothyroidism in mother and sister 
(due to Hashimoto thyroiditis) gave rise to the 
differential diagnosis of a possible primary hypothyroid 
diagnostic entity with autoimmunity in nature - 
Hashimoto’s thyroiditis in the initial phase of 
hashitoxicosis.  
 The diagnostic dilemma of the pathological 
thyroid hormone panel, which did not correlate with 
the patient`s symptoms, the underlying Hashimoto 
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thyroiditis, and the metabolic biomarkers, remained 
unclear mostly due to the still unexplained reason for 
elevated TSH levels. Additionally, the results of the 
thyroid scintigraphy presented information about an 
enlarged in volume and hyperactive thyroid gland with 
diffusely increased intensity of tracer accumulation. 
This result confirmed the prolonged TSH 
hyperstimulation effect on the thyroid gland tissue, 
correlated with the elevated FT4, FT3, TT4, and TT3 
levels and did not exclude the presence of possible 
secondary hyperthyroidism [16]. 
 To resolve the underlying reason that might 
have been responsible for for the high TSH levels, an 
MRI imaging was performed, focusing on sella turcica 
and the pituitary gland. Anatomically sound pituitary at 
native and post-contrast slice series was visualised. 
The possible presence of autonomous hyperfunctional 
pituitary adenoma (TSH-oma) was excluded. ISTHS 
can be misleading and very difficult for diagnostic 
differentiation from autonomous TSH-producing 
adenomas of the pituitary gland. Clinically, the 
patients with TSH-omas are usually hyperthyroid, and 
the ISTHS patients present euthyroid or hypothyroid 
clinical features, but both entities have a similar or 
almost identical thyroid functional laboratory profile. 
Teng X et al. have published a rare case of 
concomitant TSH-oma and peripheral resistance to 
thyroid hormones, which was not the case with our 
patient [17]. 
 To confirm or exclude the malfunctioning of 
the negative feedback loop, functional tests were 
performed. The TRH test gave important and relevant 
information. It revealed a normally responsive pituitary 
gland (TSH levels increased) by exogenous 
stimulation with TRH. 
 T3 suppression test, on the other hand, 
proved that neither the hypothalamus nor the pituitary 
gland responded to the exogenous elevated T3 values 
with decreasing the secretion of TSH and/or TRH, as 
normally would have been expected. In turn, TSH 
levels remained high despite the addition of T3, which 
indicated for the first time the presence of possible 
impaired responsiveness of the peripheral tissues to 
thyroid hormones. This also confirmed that the central 
regulation of the hypothalamus-pituitary gland-thyroid 
gland axis was sound. 
 Thyroid hormones are normally transported in 
the bloodstream bound with specific hormone carriers 
such as albumin, prealbumin, and thyroid binding 
globulin (TBG). Only a small amount of the total 
hormone release in the circulation is present in its free 
form, and that fraction is responsible for their 
peripheral effect manifestations. Abnormal protein 
bondage could be the reason for a euthyroid 
hyperthyroxinemia, as seen as in thyroid binding 
globulin (TBG) excess or familiar dysalbuminemic 
hyperthyroxinemia (FDH) [18]. But in these conditions, 
the patients usually have normal TSH levels and are 
euthyroid considering the clinical symptoms. 
Furthermore, our patient had normal protein carrier 
levels. Also, the estrogen levels in the patient were 
very low, which in turn was contradictory to the normal 
protein carrier levels since estrogen is the hormone 
which influences the regulation of their levels.  
 Thyroid hormone cell membrane transport 
defect (THCMTD) [19] refers to an abnormality of the 
MCT8 (monocarboxylate transporter 8), responsible 
for the cellular transport of the thyroid hormones so 
that they can express their effect when binding to 
nuclear receptors. They are mostly found in the brain 
and liver. But a mutation of the MCT8 generally 
affects males, since it is X chromosome-linked. Also, 
patients with MCT8 mutations usually show symptoms 
of hormone deficiency in the organs in which they are 
mostly distributed. In our patient, there were neither 
cognitive nor mental disabilities, which were 
supported by the fact of her reaching a high level of 
education. Also, MCT8 abnormality would have 
presented itself with an elevated T3 level, but low rT3 
level, low T4 level and normal or slightly elevated TSH 
level [20]. Reverse T3 (rT3) levels in our patient were 
normal, with elevated T4 and TSH, as stated 
previously. 
 Thyroid hormone metabolism defect (THMD) 
refers to the abnormal deiodinase activity, due to a 
defect in the enzyme itself (qualitative or quantitative) 
or a condition of selenium deficiency as an essential 
cofactor of the enzyme. Considering these two, our 
patient had normal rT3 levels and obvious peripheral 
conversion of FT4 into FT3. Selenium deficiency 
presents itself with high TSH and T4 levels, but low T3 
levels due to absent conversion [1]. This was not 
something that we diagnosed in our patient.  
 There are 3 types of deiodinase enzymes. 
Deiodinase I is present in the kidney, liver, thyroid and 
is responsible for 80% of the circulating T3, converted 
from T4. In this manner, any abnormal deiodinase I 
activity would have given low T3 levels - also not 
something we could see in our patient. Deiodinase II 
is found mostly in the pituitary gland, generally in the 
central nervous system, and is predominantly found 
inside the cell. In the pituitary gland, it mediates the 
negative feedback loop from the thyroid hormone 
levels. If an abnormality is present in this type of 
deiodinase, it will give rise to high values of rT3 and 
TSH, due to a lack of pituitary suppression of TSH 
production. Deiodinase III, found in CNS, placenta, 
etc., is responsible for converting T3 and T4 to its 
inactive form rT3. The decreased activity would result 
in low rT3 levels - something that was not present in 
our patient.  
 Considering the above-mentioned diagnostic 
analysis performed in our patient, we were able to 
confirm that the thyroid hormones could enter the cell, 
had a proper conversion to T3 and rT3 accordingly 
and that the patient had a weak, but yet an existing 
response to peripheral effects of the thyroid 
hormones. Though their effects had been 
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progressively decreasing as of lately, most probably 
due to the development of the Hashimoto’s thyroiditis 
(impaired thyroid hormone production at primary level) 
in the patient, we considered the possibility of present 
congenital qualitative or quantitative abnormality in the 
membrane receptor - the integrin α(V)β(3). Therefore 
this receptor became the target for the PCR 
amplification technique as the final diagnostic 
procedure performed to conclude the exact patient 
diagnosis.   
 The PCR results revealed the diagnosis of 
impaired sensitivity to thyroid hormones syndrome 
(ISTHS). A point mutation coding for the beta subunit 
of the integrin molecule α(V)β(3) was the reason why 
the patient's peripheral tissues were metabolically 
hypothyroid with high T3/FT3 and T4/FT4 circulating 
levels [21]. This qualitative change in the structure 
prevented its normal responsiveness to thyroid 
hormone stimulus, and its peptide-like action, except 
in very high quantities of the hormones present. It also 
resulted in absent suppression of TSH secretion from 
the pituitary - with extremely high TSH levels, but with 
near normal or slightly suppressed TRH due to the 
suppression of the hypothalamus from the elevated 
TSH. The treatment of the patient was by her 
symptomatology - substitutional therapy, but not 
focused on lowering the T4 and T3 levels. 
 In conclusion, peripheral resistance to thyroid 
hormones is a very rare condition and can often be 
misdiagnosed due to the broad spectrum of possible 
similar differential diagnostic entities. Molecular 
diagnostic procedures are usually required to confirm 
the exact underlying cause for the ISTHS. The 
definitive diagnostic algorithm should include not only 
the biochemical parameters but also the clinical 
patient`s symptomatology, especially in cases where 
there is a miss match between those above. 
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